Capricor Therapeutics Inc Market Cap ($521.21 Million)
Market Cap & Net Worth: Capricor Therapeutics Inc (CAPR)
Capricor Therapeutics Inc market cap. Capricor Therapeutics Inc (NASDAQ:CAPR) has a market capitalization of $521.21 Million ($521.21 Million) as of November 7, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11665 globally and #2975 in its home market, demonstrating a 35.75% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Capricor Therapeutics Inc's stock price $9.00 by its total outstanding shares 57911893 (57.91 Million). Also see Capricor Therapeutics Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Capricor Therapeutics Inc Market Cap History (2015–2026)
Capricor Therapeutics Inc market cap history from 2015 to 2026. Data shows change from $1.78 Billion to $521.21 Million (-13.51% CAGR). Check CAPR stock price for real-time trading data and today's change.
Index Memberships
Capricor Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.59 Trillion | 0.02% | #321 of 976 |
|
NASDAQ Composite
IXIC
|
$39.00 Trillion | 0.00% | #1174 of 3165 |
Weight: Capricor Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Capricor Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Capricor Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore CAPR shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
35.89x
Capricor Therapeutics Inc's market cap is 35.89 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.54 Billion | $3.19 Million | -$18.81 Million | 482.89x | N/A |
| 2017 | $915.01 Million | $1.37 Million | $2.43 Million | 669.26x | 376.33x |
| 2018 | $237.44 Million | $1.67 Million | -$15.19 Million | 142.06x | N/A |
| 2019 | $74.13 Million | $1.01 Million | -$7.64 Million | 73.76x | N/A |
| 2020 | $198.64 Million | $310.25K | -$13.66 Million | 640.25x | N/A |
| 2021 | $169.68 Million | $244.90K | -$20.02 Million | 692.87x | N/A |
| 2022 | $223.54 Million | $2.55 Million | -$29.02 Million | 87.61x | N/A |
| 2023 | $283.19 Million | $25.18 Million | -$22.29 Million | 11.25x | N/A |
| 2024 | $799.18 Million | $22.27 Million | -$40.47 Million | 35.89x | N/A |
Competitor Companies of CAPR by Market Capitalization
Companies near Capricor Therapeutics Inc in the global market cap rankings as of November 7, 2026. Also see CAPR asset base for a full breakdown of the balance sheet.
Key companies related to Capricor Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Capricor Therapeutics Inc (2015–2026)
Market capitalization of Capricor Therapeutics Inc from 2015 to today. Between 2015 and today, Capricor Therapeutics Inc's market cap moved from $1.78 Billion to $ 521.21 Million, with a yearly change of -13.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $521.21 Million | -68.81% |
| 2025 | $1.67 Billion | +109.13% |
| 2024 | $799.18 Million | +182.21% |
| 2023 | $283.19 Million | +26.68% |
| 2022 | $223.54 Million | +31.74% |
| 2021 | $169.68 Million | -14.58% |
| 2020 | $198.64 Million | +167.97% |
| 2019 | $74.13 Million | -68.78% |
| 2018 | $237.44 Million | -74.05% |
| 2017 | $915.01 Million | -40.60% |
| 2016 | $1.54 Billion | -13.46% |
| 2015 | $1.78 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Capricor Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $521.21 Million USD |
| MoneyControl | $521.21 Million USD |
| MarketWatch | $521.21 Million USD |
| marketcap.company | $521.21 Million USD |
| Reuters | $521.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treat… Read more